img

Global Hemoglobinopathy Drugs Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Hemoglobinopathy Drugs Market Research Report 2024

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin. 
According to Mr Accuracy reports new survey, global Hemoglobinopathy Drugs market is projected to reach US$ 5815.9 million in 2029, increasing from US$ 4274.5 million in 2022, with the CAGR of 4.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hemoglobinopathy Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hemoglobinopathy Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Novartis
AstraZeneca
Bluebird
Bristol-Myers Squibb
Emmaus Medical
Acceleron Pharma
HemaQuest Pharmaceuticals
Eli Lilly and Company
Celgene
Segment by Type
Hydroxyurea
Glutamine
Zynteglo
Other

Segment by Application


Sickle Cell Diseases
Thalassemia
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Hemoglobinopathy Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hemoglobinopathy Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hydroxyurea
1.2.3 Glutamine
1.2.4 Zynteglo
1.2.5 Other
1.3 Market by Application
1.3.1 Global Hemoglobinopathy Drugs Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Sickle Cell Diseases
1.3.3 Thalassemia
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hemoglobinopathy Drugs Market Perspective (2018-2029)
2.2 Hemoglobinopathy Drugs Growth Trends by Region
2.2.1 Global Hemoglobinopathy Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Hemoglobinopathy Drugs Historic Market Size by Region (2018-2024)
2.2.3 Hemoglobinopathy Drugs Forecasted Market Size by Region (2024-2029)
2.3 Hemoglobinopathy Drugs Market Dynamics
2.3.1 Hemoglobinopathy Drugs Industry Trends
2.3.2 Hemoglobinopathy Drugs Market Drivers
2.3.3 Hemoglobinopathy Drugs Market Challenges
2.3.4 Hemoglobinopathy Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hemoglobinopathy Drugs Players by Revenue
3.1.1 Global Top Hemoglobinopathy Drugs Players by Revenue (2018-2024)
3.1.2 Global Hemoglobinopathy Drugs Revenue Market Share by Players (2018-2024)
3.2 Global Hemoglobinopathy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hemoglobinopathy Drugs Revenue
3.4 Global Hemoglobinopathy Drugs Market Concentration Ratio
3.4.1 Global Hemoglobinopathy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hemoglobinopathy Drugs Revenue in 2022
3.5 Hemoglobinopathy Drugs Key Players Head office and Area Served
3.6 Key Players Hemoglobinopathy Drugs Product Solution and Service
3.7 Date of Enter into Hemoglobinopathy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hemoglobinopathy Drugs Breakdown Data by Type
4.1 Global Hemoglobinopathy Drugs Historic Market Size by Type (2018-2024)
4.2 Global Hemoglobinopathy Drugs Forecasted Market Size by Type (2024-2029)
5 Hemoglobinopathy Drugs Breakdown Data by Application
5.1 Global Hemoglobinopathy Drugs Historic Market Size by Application (2018-2024)
5.2 Global Hemoglobinopathy Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Hemoglobinopathy Drugs Market Size (2018-2029)
6.2 North America Hemoglobinopathy Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hemoglobinopathy Drugs Market Size by Country (2018-2024)
6.4 North America Hemoglobinopathy Drugs Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hemoglobinopathy Drugs Market Size (2018-2029)
7.2 Europe Hemoglobinopathy Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hemoglobinopathy Drugs Market Size by Country (2018-2024)
7.4 Europe Hemoglobinopathy Drugs Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hemoglobinopathy Drugs Market Size (2018-2029)
8.2 Asia-Pacific Hemoglobinopathy Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2018-2024)
8.4 Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hemoglobinopathy Drugs Market Size (2018-2029)
9.2 Latin America Hemoglobinopathy Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hemoglobinopathy Drugs Market Size by Country (2018-2024)
9.4 Latin America Hemoglobinopathy Drugs Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hemoglobinopathy Drugs Market Size (2018-2029)
10.2 Middle East & Africa Hemoglobinopathy Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2018-2024)
10.4 Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Hemoglobinopathy Drugs Introduction
11.1.4 Novartis Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.1.5 Novartis Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Hemoglobinopathy Drugs Introduction
11.2.4 AstraZeneca Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.2.5 AstraZeneca Recent Development
11.3 Bluebird
11.3.1 Bluebird Company Detail
11.3.2 Bluebird Business Overview
11.3.3 Bluebird Hemoglobinopathy Drugs Introduction
11.3.4 Bluebird Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.3.5 Bluebird Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Hemoglobinopathy Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Emmaus Medical
11.5.1 Emmaus Medical Company Detail
11.5.2 Emmaus Medical Business Overview
11.5.3 Emmaus Medical Hemoglobinopathy Drugs Introduction
11.5.4 Emmaus Medical Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.5.5 Emmaus Medical Recent Development
11.6 Acceleron Pharma
11.6.1 Acceleron Pharma Company Detail
11.6.2 Acceleron Pharma Business Overview
11.6.3 Acceleron Pharma Hemoglobinopathy Drugs Introduction
11.6.4 Acceleron Pharma Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.6.5 Acceleron Pharma Recent Development
11.7 HemaQuest Pharmaceuticals
11.7.1 HemaQuest Pharmaceuticals Company Detail
11.7.2 HemaQuest Pharmaceuticals Business Overview
11.7.3 HemaQuest Pharmaceuticals Hemoglobinopathy Drugs Introduction
11.7.4 HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.7.5 HemaQuest Pharmaceuticals Recent Development
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Detail
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Hemoglobinopathy Drugs Introduction
11.8.4 Eli Lilly and Company Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.8.5 Eli Lilly and Company Recent Development
11.9 Celgene
11.9.1 Celgene Company Detail
11.9.2 Celgene Business Overview
11.9.3 Celgene Hemoglobinopathy Drugs Introduction
11.9.4 Celgene Revenue in Hemoglobinopathy Drugs Business (2018-2024)
11.9.5 Celgene Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Hemoglobinopathy Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Hydroxyurea
Table 3. Key Players of Glutamine
Table 4. Key Players of Zynteglo
Table 5. Key Players of Other
Table 6. Global Hemoglobinopathy Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Hemoglobinopathy Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Hemoglobinopathy Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 9. Global Hemoglobinopathy Drugs Market Share by Region (2018-2024)
Table 10. Global Hemoglobinopathy Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Hemoglobinopathy Drugs Market Share by Region (2024-2029)
Table 12. Hemoglobinopathy Drugs Market Trends
Table 13. Hemoglobinopathy Drugs Market Drivers
Table 14. Hemoglobinopathy Drugs Market Challenges
Table 15. Hemoglobinopathy Drugs Market Restraints
Table 16. Global Hemoglobinopathy Drugs Revenue by Players (2018-2024) & (US$ Million)
Table 17. Global Hemoglobinopathy Drugs Market Share by Players (2018-2024)
Table 18. Global Top Hemoglobinopathy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathy Drugs as of 2022)
Table 19. Ranking of Global Top Hemoglobinopathy Drugs Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Hemoglobinopathy Drugs Revenue (CR5 and HHI) & (2018-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hemoglobinopathy Drugs Product Solution and Service
Table 23. Date of Enter into Hemoglobinopathy Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Hemoglobinopathy Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 26. Global Hemoglobinopathy Drugs Revenue Market Share by Type (2018-2024)
Table 27. Global Hemoglobinopathy Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Hemoglobinopathy Drugs Revenue Market Share by Type (2024-2029)
Table 29. Global Hemoglobinopathy Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 30. Global Hemoglobinopathy Drugs Revenue Market Share by Application (2018-2024)
Table 31. Global Hemoglobinopathy Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Hemoglobinopathy Drugs Revenue Market Share by Application (2024-2029)
Table 33. North America Hemoglobinopathy Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Hemoglobinopathy Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 35. North America Hemoglobinopathy Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Hemoglobinopathy Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Hemoglobinopathy Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 38. Europe Hemoglobinopathy Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Hemoglobinopathy Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 41. Asia-Pacific Hemoglobinopathy Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Hemoglobinopathy Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Hemoglobinopathy Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 44. Latin America Hemoglobinopathy Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Hemoglobinopathy Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 47. Middle East & Africa Hemoglobinopathy Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 48. Novartis Company Detail
Table 49. Novartis Business Overview
Table 50. Novartis Hemoglobinopathy Drugs Product
Table 51. Novartis Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 52. Novartis Recent Development
Table 53. AstraZeneca Company Detail
Table 54. AstraZeneca Business Overview
Table 55. AstraZeneca Hemoglobinopathy Drugs Product
Table 56. AstraZeneca Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 57. AstraZeneca Recent Development
Table 58. Bluebird Company Detail
Table 59. Bluebird Business Overview
Table 60. Bluebird Hemoglobinopathy Drugs Product
Table 61. Bluebird Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 62. Bluebird Recent Development
Table 63. Bristol-Myers Squibb Company Detail
Table 64. Bristol-Myers Squibb Business Overview
Table 65. Bristol-Myers Squibb Hemoglobinopathy Drugs Product
Table 66. Bristol-Myers Squibb Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 67. Bristol-Myers Squibb Recent Development
Table 68. Emmaus Medical Company Detail
Table 69. Emmaus Medical Business Overview
Table 70. Emmaus Medical Hemoglobinopathy Drugs Product
Table 71. Emmaus Medical Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 72. Emmaus Medical Recent Development
Table 73. Acceleron Pharma Company Detail
Table 74. Acceleron Pharma Business Overview
Table 75. Acceleron Pharma Hemoglobinopathy Drugs Product
Table 76. Acceleron Pharma Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 77. Acceleron Pharma Recent Development
Table 78. HemaQuest Pharmaceuticals Company Detail
Table 79. HemaQuest Pharmaceuticals Business Overview
Table 80. HemaQuest Pharmaceuticals Hemoglobinopathy Drugs Product
Table 81. HemaQuest Pharmaceuticals Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 82. HemaQuest Pharmaceuticals Recent Development
Table 83. Eli Lilly and Company Company Detail
Table 84. Eli Lilly and Company Business Overview
Table 85. Eli Lilly and Company Hemoglobinopathy Drugs Product
Table 86. Eli Lilly and Company Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 87. Eli Lilly and Company Recent Development
Table 88. Celgene Company Detail
Table 89. Celgene Business Overview
Table 90. Celgene Hemoglobinopathy Drugs Product
Table 91. Celgene Revenue in Hemoglobinopathy Drugs Business (2018-2024) & (US$ Million)
Table 92. Celgene Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hemoglobinopathy Drugs Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global Hemoglobinopathy Drugs Market Share by Type: 2022 VS 2029
Figure 3. Hydroxyurea Features
Figure 4. Glutamine Features
Figure 5. Zynteglo Features
Figure 6. Other Features
Figure 7. Global Hemoglobinopathy Drugs Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Hemoglobinopathy Drugs Market Share by Application: 2022 VS 2029
Figure 9. Sickle Cell Diseases Case Studies
Figure 10. Thalassemia Case Studies
Figure 11. Hemoglobinopathy Drugs Report Years Considered
Figure 12. Global Hemoglobinopathy Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 13. Global Hemoglobinopathy Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Hemoglobinopathy Drugs Market Share by Region: 2022 VS 2029
Figure 15. Global Hemoglobinopathy Drugs Market Share by Players in 2022
Figure 16. Global Top Hemoglobinopathy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hemoglobinopathy Drugs as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Hemoglobinopathy Drugs Revenue in 2022
Figure 18. North America Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 19. North America Hemoglobinopathy Drugs Market Share by Country (2018-2029)
Figure 20. United States Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. Canada Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Europe Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Hemoglobinopathy Drugs Market Share by Country (2018-2029)
Figure 24. Germany Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. France Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. U.K. Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Italy Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Russia Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Nordic Countries Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Asia-Pacific Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Hemoglobinopathy Drugs Market Share by Region (2018-2029)
Figure 32. China Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Japan Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. South Korea Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Southeast Asia Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. India Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Australia Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Latin America Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Hemoglobinopathy Drugs Market Share by Country (2018-2029)
Figure 40. Mexico Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Brazil Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Middle East & Africa Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Hemoglobinopathy Drugs Market Share by Country (2018-2029)
Figure 44. Turkey Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Saudi Arabia Hemoglobinopathy Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Novartis Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 47. AstraZeneca Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 48. Bluebird Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 50. Emmaus Medical Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 51. Acceleron Pharma Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 52. HemaQuest Pharmaceuticals Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 53. Eli Lilly and Company Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 54. Celgene Revenue Growth Rate in Hemoglobinopathy Drugs Business (2018-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries